Salmeterol injection - Neothetics

Drug Profile

Salmeterol injection - Neothetics

Alternative Names: LIPO-202; Salmeterol xinafoate - Lithera; Salmeterol xinafoate - Neothetics

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator Lithera
  • Developer Neothetics
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Subcutaneous fat disorders

Most Recent Events

  • 23 Dec 2016 Neothetics initiates enrolment in the LIPO-202-CL-31 phase II trial for Subcutaneous fat disorders in USA (NCT03005717)
  • 11 Aug 2016 The USPTO issues a patent for salmeterol injection in USA before August 2016
  • 18 Jul 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top